FibroBiologics (FBLG) EBITDA (2023 - 2026)

FibroBiologics (FBLG) has reported EBITDA for 4 consecutive years, with -$4.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA rose 10.18% year-over-year to -$4.0 million; the trailing twelve-month figure through Jun 2026 stood at -$16.7 million (down 4.0% YoY), and the FY2025 full-year result was -$16.6 million, down 21.2% from the prior year.
• EBITDA advanced to -$4.0 million in Q2 2026 per FBLG's latest filing, from -$5.1 million in the prior quarter.
• Across five years, EBITDA topped out at -$2.1 million in Q3 2023 and bottomed at -$5.1 million in Q1 2026.
• Historically, EBITDA has averaged -$3.5 million across 4 years, with a median of -$3.4 million in 2024.
• The sharpest annual moves came in 2024 and 2025: EBITDA slumped 63.35% in 2024, then jumped 30.23% in 2025.
• Over 4 years, EBITDA stood at -$2.5 million in 2023, then tumbled by 49.68% to -$3.7 million in 2024, then surged by 30.23% to -$2.6 million in 2025, then slumped by 55.71% to -$4.0 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$4.0 million, -$5.1 million, and -$2.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.